Ascentage Pharma Group International filed its 2026 Interim Report covering the six months ended June 30, 2026. Revenue increased 29.3% to RMB302.2 million (US$44.5 million), driven by a 32.6% rise in product sales to RMB282.4 million. Total operating expenses grew 36.1% to RMB1,042.7 million due to increased research and development spending of RMB697.5 million and selling expenses of RMB226.4 million for Lisaftoclax marketing. The net loss widened to RMB817.0 million (US$120.4 million) from RMB590.8 million in the prior year period, while cash balances decreased 23.3% to RMB1,895.6 million. The company appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer on August 3, 2026. Ascentage Pharma is a global biopharmaceutical company engaged in the discovery, development, and commercialization of novel cancer therapies.
